Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY 94-9343) in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies

Investigating the Safety and Efficacy of an Investigational Medication for Advanced Solid Tumors

Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors.

Detailed description of study

The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors. The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine, and to determine the MTD of anetumab ravtansine in combination with cisplatin for mesothelin expressing advanced cholangiocarcinoma and in combination with gemcitabine for mesothelin expressing advanced adenocarcinoma of the pancreas.

Participants will be compensated for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Mesothelin,Neoplasm,Neoplasms,Malignancy,Malignancies,Cancer,Oncology
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria
Availability of tumor tissue for mesothelin expression testing
Histologically-confirmed, mesothelin-expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria)
At least one measurable lesion
Adequate bone marrow, liver, renal and coagulation function
Exclusion Criteria
More than one prior anti-tubulin/microtubule agent
Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition
Symptomatic Central nervous system (CNS) metastases and/or carcinomatous meningitis
Contraindication to both CT and MRI contrast agents
Active hepatitis B or C infection
Pregnant or breast-feeding patients
Tumor type specific exclusion criteria

Updated on 19 Feb 2024. Study ID: 1706851679

This study investigates the safety and effectiveness of an investigational medication for treating advanced solid tumors that express mesothelin, a protein found on the surface of some cancer cells. The study will test the investigational medication alone or in combination with other treatments to see how well it works and how safe it is for patients.

Participants will undergo various study procedures to monitor their health and the effects of the treatment. The study will include a dose-finding phase to determine the safest dose when the investigational medication is combined with other drugs. This phase will help identify the maximum tolerated dose, which is the highest dose that does not cause unacceptable side effects.

  • Who can participate: Adults with advanced or metastatic mesothelin-expressing tumors can participate. Participants must have at least one measurable lesion and adequate organ function. Those with more than one prior anti-tubulin agent or certain medical conditions may be excluded.
  • Study details: Participants will receive either the investigational medication alone or in combination with other treatments. The study includes a dose-finding phase to ensure safety and determine the best dose levels.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here